What is it about?
The present study aims on preparing Levosulpiride loaded solid lipid nanoparticles (SLNs) to reduce the dose, frequency of dosing, reduce side effects and to increase the bioavailable fraction of drug (<30% orally in general). Levosulpiride was characterized by preformulation studies like physical appearance, melting point, assay, calibration curve, FTIR analysis and DSC analysis. The calibration curve of the drug was prepared in pH 6.8 phosphate buffer. Two lipids (Stearic acid and Palmitic acid) were used as lipid phase to prepare SLNs. Factorial design was applied to formulate 16 formulations (8 for each lipid i.e. SF1-SF8 and PF1-PF8). Levosulpiride SLNs were prepared by solvent evaporation method followed by homogenization. The optimized formulations were characterized by particle size analysis, zeta potential analysis, in vitro drug release and drug release kinetics. Drug-excipient interaction in optimized formulation was characterized by FTIR, DSC and TEM analysis. On the basis of evaluation parameters, the formulation SF1 (containing Stearic acid) and PF1 (containing Palimitic acid) found to be better formulations amongst their groups with a controlled drug release after a period of 24 hrs.
Featured Image
Why is it important?
Our finding provides a smart and effective way of delivering the drug to brain.
Perspectives
Animal studies could be performed to confirm the potential of formulated solid lipid nanoparticles in-vivo.
Dr Rajesh Kumar
Lovely Professional University
Read the Original
This page is a summary of: Formulation and Evaluation of Solid Lipid Nanoparticles Containing Levosulpiride, The Open Nanomedicine Journal, October 2017, Bentham Science Publishers,
DOI: 10.2174/1875933501704010017.
You can read the full text:
Contributors
The following have contributed to this page
